Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of remission induction with Hyper-CVAD chemotherapy in acute lymphoblastic leukemia
IRCT138806142417N1Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, vincristine, doxorubicin and dexamethasone in acute lymphoblastic leukemia (ALL), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Complete remission rate. Started Feb 2010; status: completed.
02
Drugs
cyclophosphamidevincristinedoxorubicindexamethasone
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on IRCT138806142417N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT138806142417N1.